Should clinicians continue using aspirin for patients with prior percutaneous coronary intervention who are undergoing noncardiac surgery? The answer appears to be yes based on the results of a new study from Canada.
Researchers have determined that edoxaban was noninferior to dalteparin regarding the composite outcome of recurrent VTE or major bleeding, although recurrent VTE was lower and bleeding was higher with edoxaban.
The authors of a recent study concluded that among hip or knee arthroplasty patients who receive five days of postoperative rivaroxaban, extended prophylaxis with aspirin was not significantly different from rivaroxaban in the prevention of symptomatic venous thromboembolism.
In this section: The agency tackles loperamide abuse, approves new breast cancer treatment, updates guidance on opioid cough and cold medications, promotes new opportunities to battle the opioid epidemic, and issues new indication for an irritable bowel drug.
In this section: Agency approves new diabetes treatment, green lights medicine for treatment of shock, gives the go ahead to a follow-on version of insulin lispro injection, launches a new website to assist with antibiotic selection, and removes a boxed warning from long-acting beta-agonists in combination with inhaled corticosteroids regarding asthma-related death.